Aging Clinical Trial
Official title:
Patient Pathway Pharmacist: Drug Optimisation for Hip Fracture Patients - Facilitating a Safe Patient Handover: a Descriptive Study
NCT number | NCT03695081 |
Other study ID # | 59475 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | September 3, 2018 |
Est. completion date | June 28, 2023 |
Verified date | June 2023 |
Source | Sykehuset i Vestfold HF |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Medication errors represent the most common cause of patient injury and one of the most frequently reported health related deviation in Norway. The addition of a dedicated clinical pharmacist throughout the hip fracture patient pathway (patient pathway pharmacist) is believed to improve patient safety and ensure optimal drug-related patient care. The pharmacist will perform medication reconciliation at admission to hospital, medication review after surgery and assist physicians with discharge summary. Six weeks after discharge the patient pathway pharmacist will perform a second drug reconciliation and medication review. This study will assess the pharmacists' place and specific tasks in the patient pathway, describe areas where the pharmacist contribute to increased quality of care and assess the benefits and/or disadvantages experienced with introducing a patient pathway pharmacist. The estimated number of patients included is 60. Current practice will be determined by investigating the last 50 patients' medical record and a questionnaire to health care professionals involved in treatment of hip fracture patients. Data from medication reconciliation and drug review will be collected and compared to current practice. After the inclusion period, focus group surveys and/or semi-structured interviews will be executed to describe the perceived improvement in the quality of care. Primary endpoints are: 1) Medication reconciliation score at admission 2) Number of inappropriate drugs for elderly 3) Discharge summary score 4) Discharge summaries following procedure. Secondary endpoints are readmissions and mortality after 30 and 90 days. Qualitative endpoints: 1) Health care professionals experience of current drug-related practice 2) Experienced advantages and disadvantages of a patient pathway pharmacist.
Status | Completed |
Enrollment | 60 |
Est. completion date | June 28, 2023 |
Est. primary completion date | June 15, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Hip fracture patients in Vestfold county, Norway Exclusion Criteria: - Patients under 18 years - Terminally ill - Hip fracture patients who do not follow the standardized patient pathway at Vestfold Regional Hospital - Patients who do not consent to be included in the study |
Country | Name | City | State |
---|---|---|---|
Norway | Vestfold Hospital Trust | Tønsberg |
Lead Sponsor | Collaborator |
---|---|
Sykehuset i Vestfold HF | Hospital Pharmacy Enterprise, South Eastern Norway |
Norway,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Experience of current practice | A questionnaire will be distributed to all health care professionals involved in the treatment of hip fracture patients | Prior to or during the early start of the intervention | |
Other | Experience of patient pathway pharmacist | Focus groups or semi-structured interviews will be performed to assess the advantages and/or disadvantages of introducing a patient pathway pharmacist. | Within three months after last included patient | |
Primary | Discharge summary score | In the discharge summary, the section describing drugs is scored in accordance with the national patient safety program | At discharge (estimated five days after fracture/inclusion) | |
Primary | Admission summary score | In the admission summary, the section describing drugs is scored. The score is adjusted from the discharge summary score to fit the admission note. | At hospital admission (estimated to be within 24 hours after fracture) | |
Primary | Discharge summaries written in accordance with procedure | In the discharge summary, the section describing drugs should be in accordance with procedure. | At discharge (estimated five days after fracture/inclusion) | |
Primary | Number of inappropriate drugs at discharge | After surgery the medication review may reduce the number of inappropriate drugs (on the STOPP-list). | During hospitalisation, after surgery (estimated to be within five days after fracture/inclusion) | |
Secondary | Readmission | Patients who are readmitted to hospital is quantified | 30 days after discharge | |
Secondary | Readmission | Patients who are readmitted to hospital is quantified | 90 days after discharge | |
Secondary | Death | The number patients who dies is quantified | 30 days after discharge | |
Secondary | Death | The number of patients who dies is quantified | 90 days after discharge |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Completed |
NCT05293730 -
Trial of the Impact of the Electronic Frailty Integrated With Social Needs
|
N/A | |
Recruiting |
NCT03932162 -
Gene Expression Changes In Young and Geriatric Skin
|
Early Phase 1 | |
Completed |
NCT04064528 -
Effects of Age on Amino Acid Delivery to Tendon
|
N/A | |
Completed |
NCT03366129 -
Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
|
||
Completed |
NCT06029920 -
Influence of Overground Walking on Biomarkers, Cognitive Function, and Quality of Life in Elderly With Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT05566938 -
Study to Design a Precision Nutrition Strategy at a Group Level in the Elderly
|
N/A | |
Recruiting |
NCT05543980 -
Leg Heat Therapy in Elderly Individuals
|
Phase 2 | |
Completed |
NCT04894929 -
Comprehensive Geriatric Assessment in the Monitoring of Functional Improvement
|
N/A | |
Not yet recruiting |
NCT06071130 -
Emotion, Aging, and Decision Making
|
N/A | |
Enrolling by invitation |
NCT04641663 -
Multi-target Dietary Supplement Tolerability in an Aging Population (MTDSST)
|
N/A | |
Completed |
NCT04088006 -
The Evaluation of Efficacy and Safety of Hyaluronic Acid Injection on Skin Moisturization and Elasticity
|
N/A | |
Recruiting |
NCT05424263 -
Acetate and Age-associated Arterial Dysfunction
|
Phase 2 | |
Completed |
NCT05601713 -
Mitigating Heat-induced Physiological Strain and Discomfort in Older Adults Via Lower Limb Immersion and Neck Cooling
|
N/A | |
Completed |
NCT04551339 -
Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19
|
N/A | |
Recruiting |
NCT04997577 -
Speech Perception and High Cognitive Demand
|
N/A | |
Completed |
NCT05922475 -
Efficacy of Pre-sleep or Post-exercise Protein During 12 Weeks of Resistance Exercise Training
|
N/A | |
Completed |
NCT04015479 -
Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults
|
N/A | |
Recruiting |
NCT06133634 -
Fisetin to Improve Vascular Function in Older Adults
|
Phase 1/Phase 2 |